98%
921
2 minutes
20
Dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) are two common types of cardiomyopathies leading to heart failure. Accurate diagnostic classification of different types of cardiomyopathies is critical for precision medicine in clinical practice. In this study, we hypothesized that machine learning (ML) can be used as a novel diagnostic approach to analyze cardiac transcriptomic data for classifying clinical cardiomyopathies. RNA-Seq data of human left ventricle tissues were collected from 41 DCM patients, 47 ICM patients, and 49 nonfailure controls (NF) and tested using five ML algorithms: support vector machine with radial kernel (svmRadial), neural networks with principal component analysis (pcaNNet), decision tree (DT), elastic net (ENet), and random forest (RF). Initial ML classifications achieved ~93% accuracy (svmRadial) for NF vs. DCM, ~82% accuracy (RF) for NF vs. ICM, and ~80% accuracy (ENet and svmRadial) for DCM vs. ICM. Next, 50 highly contributing genes (HCGs) for classifying NF and DCM, 68 HCGs for classifying NF and ICM, and 59 HCGs for classifying DCM and ICM were selected for retraining ML models. Impressively, the retrained models achieved ~90% accuracy (RF) for NF vs. DCM, ~90% accuracy (pcaNNet) for NF vs. ICM, and ~85% accuracy (pcaNNet and RF) for DCM vs. ICM. Pathway analyses further confirmed the involvement of those selected HCGs in cardiac dysfunctions such as cardiomyopathies, cardiac hypertrophies, and fibrosis. Overall, our study demonstrates the promising potential of using artificial intelligence via ML modeling as a novel approach to achieve a greater level of precision in diagnosing different types of cardiomyopathies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509247 | PMC |
http://dx.doi.org/10.1152/physiolgenomics.00063.2020 | DOI Listing |
Rev Cardiovasc Med
August 2025
Department of Cardiology, Gansu Provincial People's Hospital, 730000 Lanzhou, Gansu, China.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a promising new class of drugs, whose clinical potential has recently been explored. Various preclinical studies and clinical trials initially demonstrated the efficacy of GLP-1RAs in treating type 2 diabetes mellitus (T2DM). However, long-term clinical practice has revealed that GLP-1RAs also exhibit significant efficacy and preventive effects in cardiovascular diseases.
View Article and Find Full Text PDFCardiovasc Res
September 2025
Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA.
Aims: Although the ability of the heart to adapt to environmental stress has been studied extensively, the molecular and cellular mechanisms responsible for cardioprotection are not yet fully understood. In this study, we sought to elucidate these mechanisms for cytoprotection using a model of stress-induced cardiomyopathy.
Methods And Results: We administered Toll-like receptor (TLR) agonists or diluent to wild-type mice and assessed for cardioprotection against injury from a high intraperitoneal dose of isoproterenol (ISO) administered 7 days later.
Biomed Eng Lett
September 2025
Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, China.
Abstract: Hypertrophic cardiomyopathy (HCM) is a common hereditary heart disease and is the leading cause of sudden cardiac death in adolescents. Septal hypertrophy (SH) and apical hypertrophy (AH) are two common types. The former is characterized by abnormal septal myocardial thickening and the latter by left ventricular apical hypertrophy, both of which significantly increase the risk of heart failure, arrhythmias, and other serious complications.
View Article and Find Full Text PDFInt J Artif Organs
September 2025
Department of Clinical Engineering, Faculty of Medical Science and Technology, Gunma Paz University, Takasaki-shi, Gunma, Japan.
Cardiovascular disease (CVD) is a leading cause of death worldwide. CVD includes conditions such as myocardial infarction (MI), arrhythmias, valvular heart disease, and cardiomyopathy. The limitations of heart treatment are related to the inability of damaged cells to regenerate, which leads to an increasing demand for new therapies.
View Article and Find Full Text PDFBackground: Activating Transcription Factor 4 (ATF4) functions as a transcriptional regulator in various cell types and tissues under both physiological and pathological conditions. While previous studies have linked ATF4 activation with promoting cardiomyocyte (CM) death in dilated cardiomyopathy (DCM), atrial fibrillation, and heart failure, its role in developing CMs remains unexplored.
Methods: We generated multiple distinct CM-specific ( , and ) and global knockout ( and ) mouse models targeting different regions, as well as cardiomyocyte-specific deletion of to study cardiac phenotypes.